symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
BICTF,0.07,2.533975,17,5712252,0,0.0035-0.07,0.0388,Biocure Technology Inc.,USD,,,,Other OTC,PNK,Biotechnology,https://www.biocuretech.com,"Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ÃŸ for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions. It also engages in the research and development of CAR T Cell therapy that identifies and destroys cancer cells; a foot and mouth disease vaccine; and hair growth products. The company was founded in 2005 and is headquartered in Vancouver, Canada.",Mr. Yee Sing Cheng,Healthcare,CA,,,1055 West Hastings Street,Vancouver,BC,V6E 2E9,,0,https://financialmodelingprep.com/image-stock/BICTF.png,2018-11-28,True,False,False,False,False
